Overview of Voting Rights and Share Capital
Voting rights are integral to corporate governance, allowing shareholders a voice in significant company decisions. Understanding these rights is essential for anyone considering investing in a company, such as Nanobiotix, listed under the ticker symbols Paris:NANO and Nasdaq: NBTX. This article delves into the fundamental principles of voting rights, share capital, and how they impact investor involvement.
Understanding Voting Rights
The voting rights associated with shares grant shareholders the power to influence key decisions, including the election of board members, mergers, and changes to company policies. These rights can be categorized into theoretical and exercisable voting rights. Theoretical voting rights consider all shares eligible to vote, while exercisable voting rights account for shares actively engaged in votes.
The Importance of Voting Rights
For investors, voting rights are vital as they ensure a degree of control over the company’s operations and strategic direction. A shareholder with more voting rights has a greater influence on governance compared to those with fewer. In the context of Nanobiotix, shareholders can exercise their rights at annual meetings, presenting an opportunity to affect the direction of a pioneering biotechnology firm.
Current Share Capital Status
The share capital of a company refers to the total monetary value of shares issued to shareholders. It provides insights into the financing structure and stability of a company. In the case of Nanobiotix, there are several points of interest regarding its share capital that investors should be aware of.
Recent Share Capital Data
As of the latest reports, Nanobiotix had 47,426,851 shares outstanding as of December 31, 2024. The total theoretical voting rights stood at 49,204,910 while the exercisable voting rights were recorded at 49,182,792. This data reflects a healthy share structure that engages shareholders in the corporate decision-making process.
About Nanobiotix
Founded in 2003 and headquartered in Paris, France, Nanobiotix is a clinical biotechnology company specializing in advanced therapeutic solutions. The company operates with a mission to revolutionize treatment outcomes for various medical conditions through innovative nanotechnology. With a commitment to pushing the boundaries of science, Nanobiotix focuses on several therapeutic areas, primarily oncology and central nervous system disorders.
Patents and Innovations
Nanobiotix's dedication to research and development is evident through its extensive portfolio of over 25 patent families associated with nanotechnology platforms. These innovations are crucial for maintaining a competitive edge in the biotechnology sector. The company continues to work towards breakthroughs that can enhance patient care significantly.
Investor Knowing
Understanding the dynamics of voting rights and share capital can empower investors to make informed decisions. Nanobiotix, listed on both Euronext Paris and Nasdaq, offers investors the unique opportunity to participate in the growth of a promising biotech firm aiming to create a meaningful impact on healthcare.
Contact Information for Investors
For inquiries regarding investor relations, interested parties may reach out to Craig West, Senior Vice President of Investor Relations at Nanobiotix. He can be contacted at +1 (617) 583-0211 for further information.
Frequently Asked Questions
1. What are voting rights in a company?
Voting rights allow shareholders to participate in decision-making processes regarding key company matters, influencing governance and strategic direction.
2. How is share capital defined?
Share capital represents the total monetary value of shares issued to shareholders, reflecting the financial health and support for operations in the company.
3. Why are exercisable voting rights significant?
Exercisable voting rights show the actual votes that shareholders can cast at meetings, directly impacting decisions based on active participation.
4. How does Nanobiotix's share capital affect investors?
Nanobiotix's share capital structure provides insights into its stability and growth potential, making it an important aspect for prospective investors.
5. Who can I contact for investor-related questions at Nanobiotix?
For investor inquiries, reach out to Craig West, SVP of Investor Relations, at +1 (617) 583-0211.
